ERBB2 and neoplasm: Trastuzumab docarmazine (SYD985) and disitamab vedotin have demonstrated efficacy against tumor cells and are also being tested for efficacy and safety in clinical trials in HER2+ metastatic disease (NCT03262935, NCT03500380).